[
  {
    "ts": null,
    "headline": "AbbVie Inc. stock underperforms Tuesday when compared to competitors",
    "summary": "AbbVie Inc. stock underperforms Tuesday when compared to competitors",
    "url": "https://finnhub.io/api/news?id=d300bf4c123c1b691c3a4b0c7ccdf3d7ebf0e67630a9ba9f52d23f2dc0f257a4",
    "source": "MarketWatch",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1733848500,
      "headline": "AbbVie Inc. stock underperforms Tuesday when compared to competitors",
      "id": 131933393,
      "image": "",
      "related": "ABBV",
      "source": "MarketWatch",
      "summary": "AbbVie Inc. stock underperforms Tuesday when compared to competitors",
      "url": "https://finnhub.io/api/news?id=d300bf4c123c1b691c3a4b0c7ccdf3d7ebf0e67630a9ba9f52d23f2dc0f257a4"
    }
  },
  {
    "ts": null,
    "headline": "Buy 1 December Aristocrat Of 67 From 38 With 'Safer' Dividends",
    "summary": "67 Aristocrats span all sectors, with BEN topping yields. Read why its strong dividend history and low price make it a December buy, despite analyst concerns.",
    "url": "https://finnhub.io/api/news?id=b7d91ae2ae781cb668d998e7e5af207aba8601a46994e0e31da4474ab4afa404",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1733845375,
      "headline": "Buy 1 December Aristocrat Of 67 From 38 With 'Safer' Dividends",
      "id": 131907202,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1157043971/image_1157043971.jpg?io=getty-c-w1536",
      "related": "ABBV",
      "source": "SeekingAlpha",
      "summary": "67 Aristocrats span all sectors, with BEN topping yields. Read why its strong dividend history and low price make it a December buy, despite analyst concerns.",
      "url": "https://finnhub.io/api/news?id=b7d91ae2ae781cb668d998e7e5af207aba8601a46994e0e31da4474ab4afa404"
    }
  },
  {
    "ts": null,
    "headline": "AbbVie's Recently Acquired Parkinson's Drug Meets Third Study Goal",
    "summary": "Data from a late-stage study shows that treatment with flexible doses of ABBV's tavapadon reduced the burden of Parkinson's disease.",
    "url": "https://finnhub.io/api/news?id=ec203d3e5dce7829b288df0aeee816ef9fd3979705b18d30750a6de99dc2d9b0",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1733845140,
      "headline": "AbbVie's Recently Acquired Parkinson's Drug Meets Third Study Goal",
      "id": 131905069,
      "image": "https://media.zenfs.com/en/zacks.com/6c915f5bdd1c7ea850acb1ca1c067326",
      "related": "ABBV",
      "source": "Yahoo",
      "summary": "Data from a late-stage study shows that treatment with flexible doses of ABBV's tavapadon reduced the burden of Parkinson's disease.",
      "url": "https://finnhub.io/api/news?id=ec203d3e5dce7829b288df0aeee816ef9fd3979705b18d30750a6de99dc2d9b0"
    }
  },
  {
    "ts": null,
    "headline": "Pioneer Balanced ESG Fund Q3 2024 Performance And Market Commentary",
    "summary": "Pioneer Balanced ESG Fundâs Class Y shares returned 4.09% in the third quarter, underperforming the Fundâs equity and fixed income benchmarks. Read more here.",
    "url": "https://finnhub.io/api/news?id=342ef00ffdf9360c3d2a739a17135c531918eea0645a9234bd618c6fc0d2e531",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1733836140,
      "headline": "Pioneer Balanced ESG Fund Q3 2024 Performance And Market Commentary",
      "id": 131905014,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1401878862/image_1401878862.jpg?io=getty-c-w1536",
      "related": "ABBV",
      "source": "SeekingAlpha",
      "summary": "Pioneer Balanced ESG Fundâs Class Y shares returned 4.09% in the third quarter, underperforming the Fundâs equity and fixed income benchmarks. Read more here.",
      "url": "https://finnhub.io/api/news?id=342ef00ffdf9360c3d2a739a17135c531918eea0645a9234bd618c6fc0d2e531"
    }
  },
  {
    "ts": null,
    "headline": "AbbVie's (NYSE:ABBV) Shareholders Will Receive A Bigger Dividend Than Last Year",
    "summary": "The board of AbbVie Inc. ( NYSE:ABBV ) has announced that it will be paying its dividend of $1.64 on the 14th of...",
    "url": "https://finnhub.io/api/news?id=327be05ba87529e303c21f0b58007a99912fbea8418a46f18ed134be58dca236",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1733827098,
      "headline": "AbbVie's (NYSE:ABBV) Shareholders Will Receive A Bigger Dividend Than Last Year",
      "id": 131903658,
      "image": "https://media.zenfs.com/en/simply_wall_st__316/b1235bf6d18ebc2cd7323427468d0693",
      "related": "ABBV",
      "source": "Yahoo",
      "summary": "The board of AbbVie Inc. ( NYSE:ABBV ) has announced that it will be paying its dividend of $1.64 on the 14th of...",
      "url": "https://finnhub.io/api/news?id=327be05ba87529e303c21f0b58007a99912fbea8418a46f18ed134be58dca236"
    }
  },
  {
    "ts": null,
    "headline": "AbbVie’s Phase III trial of Parkinson’s disease treatment meets primary endpoint",
    "summary": "The company plans to submit a new drug application for tavapadon to the US Food and Drug Administration next year.",
    "url": "https://finnhub.io/api/news?id=4b874fc673c7493984ae4a4d5ba22adafea3bad67e159813a27f7d3e4562abe4",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1733826048,
      "headline": "AbbVie’s Phase III trial of Parkinson’s disease treatment meets primary endpoint",
      "id": 131903659,
      "image": "https://live-b2b-gdm-figaro1.pantheonsite.io/wp-content/uploads/sites/22/2024/12/CTA-1-AbbVie.jpg",
      "related": "ABBV",
      "source": "Yahoo",
      "summary": "The company plans to submit a new drug application for tavapadon to the US Food and Drug Administration next year.",
      "url": "https://finnhub.io/api/news?id=4b874fc673c7493984ae4a4d5ba22adafea3bad67e159813a27f7d3e4562abe4"
    }
  },
  {
    "ts": null,
    "headline": "The Zacks Analyst Blog Highlights Eli Lilly, AbbVie, Gilead Sciences, Air T and Fossil Group",
    "summary": "Eli Lilly, AbbVie, Gilead Sciences, Air T and Fossil Group are included in this Analyst Blog.",
    "url": "https://finnhub.io/api/news?id=ca26fff1d5cb793489ed35def3676a8c50d60227996c5c720beed96308b4eec3",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1733824800,
      "headline": "The Zacks Analyst Blog Highlights Eli Lilly, AbbVie, Gilead Sciences, Air T and Fossil Group",
      "id": 131903660,
      "image": "https://media.zenfs.com/en/zacks.com/60c096e1e24bb285c41a58d325d8d707",
      "related": "ABBV",
      "source": "Yahoo",
      "summary": "Eli Lilly, AbbVie, Gilead Sciences, Air T and Fossil Group are included in this Analyst Blog.",
      "url": "https://finnhub.io/api/news?id=ca26fff1d5cb793489ed35def3676a8c50d60227996c5c720beed96308b4eec3"
    }
  },
  {
    "ts": null,
    "headline": "Dividend Income Summary: Lanny's November 2024 Summary",
    "summary": "Investing in dividend stocks allows you to earn dividend income, the best passive income stream.",
    "url": "https://finnhub.io/api/news?id=a91eab9caf7e1a3c19c22535d94dec4f78bc068f12e8ed32e2d845b8f3bf7115",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1733819400,
      "headline": "Dividend Income Summary: Lanny's November 2024 Summary",
      "id": 131901451,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1365758819/image_1365758819.jpg?io=getty-c-w1536",
      "related": "ABBV",
      "source": "SeekingAlpha",
      "summary": "Investing in dividend stocks allows you to earn dividend income, the best passive income stream.",
      "url": "https://finnhub.io/api/news?id=a91eab9caf7e1a3c19c22535d94dec4f78bc068f12e8ed32e2d845b8f3bf7115"
    }
  },
  {
    "ts": null,
    "headline": "IGD Continues To Show Improvements, Now Covering Distribution",
    "summary": "Voya Global Equity Dividend and Premium Opportunity Fund offers a high 10.70% yield, higher than most of its peers. Find out my recommendation for IGD.",
    "url": "https://finnhub.io/api/news?id=5b7fd69f4bbfaff38f7d4e61d556a8a153124983bf45ed294724a3c30f5b584c",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1733806621,
      "headline": "IGD Continues To Show Improvements, Now Covering Distribution",
      "id": 131899192,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/88621226/image_88621226.jpg?io=getty-c-w1536",
      "related": "ABBV",
      "source": "SeekingAlpha",
      "summary": "Voya Global Equity Dividend and Premium Opportunity Fund offers a high 10.70% yield, higher than most of its peers. Find out my recommendation for IGD.",
      "url": "https://finnhub.io/api/news?id=5b7fd69f4bbfaff38f7d4e61d556a8a153124983bf45ed294724a3c30f5b584c"
    }
  }
]